Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
gptkb:cobimetinib
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
improved overall survival
improved progression-free survival |
| gptkbp:brand |
gptkb:Cotellic
|
| gptkbp:chemicalFormula |
C19H19ClN6O2S
|
| gptkbp:clinicalTrials |
Cohort Study
Phase III monotherapy or in combination therapy |
| gptkbp:contraindication |
hypersensitivity_to_cobimetinib
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:historical_analysis |
safety studies
retrospective studies real-world evidence studies prospective studies long-term safety studies pharmacokinetics studies clinical efficacy studies combination therapy studies drug interaction studies biomarker_studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Cobimetinib
|
| gptkbp:interactsWith |
strong CYP3A inducers
strong CYP3A inhibitors |
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2015
|
| gptkbp:mandates |
BRAF V600E or V600K mutation-positive melanoma
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States gptkb:Cotellic |
| gptkbp:numberOfStudents |
approximately 50 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
cancer therapy
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
risk of liver problems
risk of blood clots risk of eye problems risk of severe skin rash |
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
MEK1_and_MEK2
|
| gptkbp:triggerType |
MEK_inhibitor
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:variant |
vemurafenib
|
| gptkbp:waterManagement |
bile
|